Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
ApexOnco Front Page
Recent articles
Pivotal data set the stage for slightly delayed US accelerated approval filing.
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
First-in-human trial starts include 3SBio's SSGJ-708 and in vivo Car-Ts from Legend and Starna.
PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.
Roche dumps another partnered asset.
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
